Novo Wins EU Approval for Deal to Acquire Catalent Plants.

Novo Holdings, a major shareholder of Novo Nordisk A/S, has received approval from the European Union to acquire Catalent Inc. The deal, valued at $16.5 billion, will not raise competition concerns in the European Economic Area. Novo is expanding its operations to meet the growing demand for its weight-loss drug Wegovy and diabetes treatment Ozempic. While the EU has approved the acquisition, there may be further scrutiny from regulators in the United States. [Extracted from the article]